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1. Introduction
Many different types of adverse event are routinely recorded 
during clinical trials. The statistical analysis of this data may need 
to take into account:
1.potential multiple comparison issues;
2.low power - effect sizes of adverse events in clinical trials are 
generally small.
The use of methods which use possible groupings of adverse 
events (e.g. by System Organ Class) in their statistical analyses 
may result in an increase in the power to detect adverse event 
incidence while maintaining control over the Type-I error rate. 
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2. System Organ Class
Medical dictionaries (e.g. MedDRA) provide groupings of adverse 
events by System Organ Class (SOC).
3. Methods
Berry and Berry (2004): A Binomial Bayesian three-level 
hierarchical model where the increase in log-odds (θbj) of the 
occurrence of an adverse event under treatment is modelled as a 
mixture distribution:
The system organ classes and averse events are indexed by b 
and j respectively, and each system organ class has a common 
mean and variance.
Double False Discovery Rate (DFDR) (2012): Application of the 
False Discovery Rate at both the System Organ Class and 
individual adverse event level.
Group Benjamini-Hochberg (GBH) (2010): A p-value weighted 
application of the False Discovery Rate where groupings of 
hypotheses are used to calculate the weightings.
6. Software Implementation
All of the methods are implemented in the R package c212 (https://CRAN.R-project.org/package=c212).
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4. Clinical Trial Safety Study
23 SOCs, 497 types of adverse event. Diarrhoea and Rash were 
expected adverse events based on Phase I/II studies. At the end of 
the trial 10 adverse events were significant at 5% level for a Fisher 
exact test comparing treatment with control.
Adverse Events p-value Berry and Berry 
model¶
DFDR¤ GBH¤
Diarrhoea <0.001* 1.000 Y Y
Rash <0.001* 1.000 Y Y
Epistaxis 0.004 0.980 N N
Dyspepsia 0.004 0.986 N N
Dermaiis acneiform 0.008 0.967 N N
Muscle spasms 0.035 0.892 N N
Localised infecion 0.038 0.772 N N
Arthralgia 0.039 0.905 N N
Back pain 0.047 0.879 N N
Nail disorder 0.049 0.941 N N
* Remains significant after the application of the Bonferonni correction.
¶ Posterior probability that the change in log-odds of the occurrence of the adverse event on the treatment arm 
is positive.
¤ Flagged as significant by the procedure at the 5% or 10% significance level (Y = yes, N = no).
Under the Berry and Berry model 5 adverse events have posterior 
probability exceeding 0.95 of increased treatment log-odds, 
compared to 2 adverse events flagged by a standard analysis.
5. Extended Methods – Interim Analyses
The Berry and Berry model may be extended for use at interim analyses by dividing the trial duration into intervals and considering both 
the time in study of the patients and the number of adverse events that occur over each interval of the trial. If the trial is split into H 
intervals, with B SOCs, kb adverse events in SOC b, and C different covariate patterns among the data, then the data model is:
 
where         is the set of patients with covariate pattern c at risk of the jth adverse event in SOC b at the start of interval h, and 
tih is the time patient i spends in interval h.
